Growing interest in emerging biologics such as bispecific antibodies and viral vectors is driving cell line development teams to optimize existing techniques and investigate new technologies.
Media and buffer solutions are critical for all stages of biopharmaceutical development, from sustaining living cells to purifying and stabilizing biological products.
There was a flurry of activity on social media in June when John Erickson et al. published in Biotechnology and Bioengineering on end-to-end collaboration to transform development and manufacturing of biopharmaceuticals.
i3 is our premier annual customer event where we bring together science, IT and R&D business leaders to share ideas, create new insights and advance innovation!
In a recent survey of biopharma development teams, participants reported spending an average of 1 day each week, or 20% of their time on data administration.
Being built on AWS provides plentiful opportunities as a basis for offering a SaaS solution. IDBS not only utilizes the benefits of scalable services, but also the infrastructure performance and operational stability required when offering an enterprise scale solution. Continuously added AWS services and innovations are implemented to further broaden the product offering and portfolio
Managing bioprocess data is a complex challenge even if you run just a few experiments per month. With HTPD this can quickly scale up to hundreds of automated, parallelized experiments. Used effectively as part of a BioPharma Lifecycle Management strategy, the data generated from HTPD can accelerate development by supporting better decision making and reducing timelines.
IDBS Polar Bioprocess seamlessly integrates both process and analytical data throughout your workflows to deliver greater insight, enabling you to optimize upstream unit operations for maximum productivity.
In this webinar IDBS will share how an innovative approach to biopharma lifecycle management supports true QbD and can accelerate development to bring products to market faster.
One of the lasting legacies of the COVID-19 pandemic is heightened awareness of manufacturing challenges and supply chain vulnerabilities in the biopharma industry and the impact this can have on public health. Issues have occurred at every stage of the supply chain, from the availability of raw materials to quality concerns with active pharmaceutical ingredients (APIs), and finished dosage forms and restrictive cold chain requirements.